Patients were identified by ICD-10 codes associated with hereditary disposition of malignancy (Z15.01, Z15.02, Z15.09, Z15.89, C50.919, Q99.8, C54.1). Patients with BRCA1 and BRCA2 pathogenic mutations with and without a personal history of cancer were included in this study; BRCA1/2 not ...
Methods BRCA1/2 mutation carriers were retrospectively identified from electronic medical records using ICD-10 codes, and BRCA1/2 mutation carriers between the ages of 18 and 50 seen between January 1, 2017 and August 1, 2020 were included in the study. CPT codes were used to identify ...
BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (>20 TILs/core), low/intermediate CD4+ (<20 TILs/core) and high CD8+/CD4+ ratio (>35/core) were associated with favorable out...
This is the first study to evaluate the secretory function of salivary glands, biomarkers of redox balance, and oxidative damage to proteins and lipids in the saliva of subjects with the BRCA1 mutation. Ninety eight women were enrolled in the study and allocated to four groups based on ...
The lifetime risk for breast and ovarian cancer rises dramatically for BRCA mutation germline carriers compared to the general population (Figure 1). The overall risk varies by family history, type and location of the mutation, age at diagnosis, parity (number of term pregnancies), environmental ...
Patients were identified by ICD-10 codes associated with hereditary disposition of malignancy (Z15.01, Z15.02, Z15.09, Z15.89, C50.919, Q99.8, C54.1). Inclusion criteria were patients with BRCA1 and BRCA2 pathogenic mutations who underwent genetic testing between 2009-2018. Patients with unknown...